New drug HLX43 targets stomach cancer in Mid-Stage trial

NCT ID NCT07115485

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing an experimental drug called HLX43 in 60 people with advanced gastric or gastroesophageal junction cancer. HLX43 is a targeted therapy that delivers a potent chemotherapy agent directly to cancer cells. The study aims to find the best dose and see how well the drug shrinks tumors and controls the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX43 (an antibody-drug conjugate that targets PD-L1 and delivers a chemotherapy-like drug to cancer cells)
What this could lead to: If successful, this could provide a new treatment option for people with advanced gastric or gastroesophageal junction cancer that has not responded to other therapies.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.